S
Sandra Goble
Researcher at University of Glasgow
Publications - 58
Citations - 3423
Sandra Goble is an academic researcher from University of Glasgow. The author has contributed to research in topics: Rucaparib & Population. The author has an hindex of 14, co-authored 48 publications receiving 2195 citations.
Papers
More filters
Journal ArticleDOI
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
Robert L. Coleman,Amit M. Oza,Domenica Lorusso,Carol Aghajanian,Ana Oaknin,Andrew Dean,Nicoletta Colombo,Johanne I Weberpals,Andrew R Clamp,Giovanni Scambia,Alexandra Leary,Robert W Holloway,Margarita Amenedo Gancedo,Peter C.C. Fong,Jeffrey C. Goh,David M. O'Malley,Deborah K. Armstrong,Jesus Garcia-Donas,Elizabeth M. Swisher,Anne Floquet,Gottfried E. Konecny,Iain A. McNeish,Clare L. Scott,Terri Cameron,Lara Maloney,Jeff Isaacson,Sandra Goble,Caroline Grace,Thomas Harding,Mitch Raponi,James Sun,Kevin K. Lin,Heidi Giordano,Jonathan A. Ledermann,Martin Buck,A Dean,Michael Friedlander,J C Goh,Paul R. Harnett,G Kichenadasse,C L Scott,H Denys,Luc Dirix,Ignace Vergote,Laurie Elit,Prafull Ghatage,Amit M. Oza,Marie Plante,Diane Provencher,J I Weberpals,Stephen Welch,A Floquet,Laurence Gladieff,Florence Joly,A Leary,Alain Lortholary,Jean-Pierre Lotz,J. Medioni,Olivier Tredan,Benoit You,A El-Balat,C Hänle,P Krabisch,T Neunhöffer,M Pölcher,Pauline Wimberger,Amnon Amit,S Kovel,M Leviov,Tamar Safra,Ronnie Shapira-Frommer,Salomon M. Stemmer,Alessandra Bologna,N Colombo,Domenica Lorusso,Sandro Pignata,Roberto Sabbatini,G Scambia,Stefano Tamberi,Claudio Zamagni,P C Fong,A O'Donnell,M Amenedo Gancedo,A Casado Herraez,J Garcia-Donas,E M Guerra,A Oaknin,I Palacio,Iris L. Romero,A Sanchez,Susana Banerjee,A Clamp,Y Drew,Hani Gabra,D Jackson,Jonathan A. Ledermann,I A McNeish,Christine Parkinson,Melanie E Powell,C Aghajanian,D K Armstrong,Michael J. Birrer,Mary K. Buss,Setsuko K. Chambers,L-m Chen,Robert L. Coleman,R W Holloway,G E Konecny,L Ma,Mark A. Morgan,R T Morris,David G. Mutch,D M O'Malley,B M Slomovitz,E M Swisher,T Vanderkwaak,M Vulfovich +116 more
TL;DR: This trial assessed rucaparib versus placebo after response to second-line or later platinum-based chemotherapy in patients with high-grade, recurrent, platinum-sensitive ovarian carcinoma harbouring a BRCA mutation or high percentage of genome-wide loss of heterozygosity.
Journal ArticleDOI
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial
Elizabeth M. Swisher,Kevin K. Lin,Amit M. Oza,Clare L. Scott,Heidi Giordano,James Sun,Gottfried E. Konecny,Robert L. Coleman,Anna V. Tinker,David M. O'Malley,Rebecca Kristeleit,Ling Ma,Katherine M. Bell-McGuinn,James D. Brenton,Janiel M. Cragun,Ana Oaknin,Isabelle Ray-Coquard,Maria I. Harrell,Elaina Mann,Scott H. Kaufmann,Anne Floquet,Alexandra Leary,Thomas Harding,Sandra Goble,Lara Maloney,Jeff Isaacson,Andrew R. Allen,Lindsey Rolfe,Roman Yelensky,Mitch Raponi,Iain A. McNeish +30 more
TL;DR: The ability of tumour genomic LOH, quantified with a next-generation sequencing assay, to predict response to rucaparib, an oral PARP inhibitor, was assessed in ARIEL2, an international, multicentre, two-part, phase 2, open-label study.
Journal ArticleDOI
Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2
Amit M. Oza,Anna V. Tinker,Ana Oaknin,Ronnie Shapira-Frommer,Iain A. McNeish,Elizabeth M. Swisher,Isabelle Ray-Coquard,Katherine M. Bell-McGuinn,Robert L. Coleman,David M. O'Malley,Alexandra Leary,Lee-may Chen,Diane Provencher,Ling Ma,James D. Brenton,Gottfried E. Konecny,Cesar M. Castro,Heidi Giordano,Lara Maloney,Sandra Goble,Kevin K. Lin,James Sun,Mitch Raponi,Lindsey Rolfe,Rebecca Kristeleit +24 more
TL;DR: Rucaparib has antitumor activity in advanced BRCA1/2-mutated HGOC and a manageable safety profile and investigator-assessed confirmed objective response rate (ORR).
Journal ArticleDOI
A Phase I-II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline BRCA1/2-Mutated Ovarian Carcinoma or Other Solid Tumors
Rebecca Kristeleit,Geoffrey I. Shapiro,Howard A. Burris,Amit M. Oza,Patricia LoRusso,Manish R. Patel,Susan M. Domchek,Judith Balmaña,Yvette Drew,Lee-may Chen,Tamar Safra,Tamar Safra,Ana Montes,Heidi Giordano,Lara Maloney,Sandra Goble,Jeff Isaacson,Jim J. Xiao,Jen Borrow,Lindsey Rolfe,Ronnie Shapira-Frommer +20 more
TL;DR: Rucaparib was tolerable and had activity in patients with platinum-sensitive germline BRCA1/2–mutated HGOC, and the recommended phase II dose (RP2D) was selected based on manageable toxicity and clinical activity.
Journal ArticleDOI
Rucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation.
Rachna T. Shroff,Andrew Eugene Hendifar,Robert R. McWilliams,Ravit Geva,Ron Epelbaum,Lindsey Rolfe,Sandra Goble,Kevin K. Lin,Andrew V. Biankin,Heidi Giordano,Robert H. Vonderheide,Susan M. Domchek +11 more
TL;DR: Rucaparib provided clinical benefit to patients with advanced pancreatic cancer and a BRCA1/2 mutation, and demonstrated an acceptable safety profile.